Articles

The results from a trial evaluating the Genomic Prostate Score did not find an increase in active surveillance acceptance amongst a population of predominantly Black men with favorable-risk prostate cancer.

Genomic Test Does Not Increase Active Surveillance Acceptance for Treating Favorable-Risk Prostate Cancer

The Association for Clinical Oncology cites expanded patient access and health equity as reasons for implementing broader telehealth coverage across the United States. 

ASCO Submits Comments to Congress Supporting Advanced Measures to Facilitate Telehealth Access

Results presented at part of the European Society for Medical Oncology Virtual Plenary show positive results of a phase 3 trial comparing cemiplimab with chemotherapy for previously treated cervical cancer. 

Cemiplimab Improves OS Versus Chemotherapy Across Histologic Subtypes in Recurrent Cervical Cancer

Investigators assessed a 2-part study to investigate the prognostic impact of certain clinical features and genomic markers for rucaparib in treating patients with relapsed high-grade ovarian carcinoma.

Platinum Sensitivity, Genomic Markers Associated With Rucaparib Response for High-Grade Ovarian Carcinoma

Pembrolizumab plus chemotherapy as neoadjuvant therapy followed by adjuvant monotherapy in patients with early triple-negative breast cancer was superior in terms of event-free survival versus matched placebo. 

KEYNOTE-522 Meets EFS End Point in High-Risk, Early TNBC

Videos

A clinical pharmacy specialist discusses what’s needed to get the REMS program set up and touches on reimbursement considerations for the administration of belantamab mafodotin in patients with multiple myeloma. 

Kathryn Maples, PharmD, BCOP, on Key Considerations for Belantamab Mafodotin Administration in Multiple Myeloma 

According to an economic evaluation, the use of atezolizumab plus bevacizumab is not cost effective versus sorafenib for the treatment of hepatocellular carcinoma when considering life-years gained and willingness-to-pay thresholds. 

Analysis Correlates Cost of Therapy With Improvement in Outcomes for Patients With HCC

A technology that uses AI to deliver focal laser therapy to prostate tumors was granted breakthrough device designation by the FDA, which will allow for the swift development and commercialization of the product.

FDA Breakthrough Device Designation Is Granted to Avenda Health for Laser Ablation System in Prostate Cancer

The long-term equivalence trial examined the rates of ipsilateral breast tumor recurrence for patients receiving electron intraoperative radiotherapy and whole-breast irradiation at 5-, 10-, and 15-year follow-up times.

Electron Intraoperative Radiotherapy Associated With Increased IBTR Rates for Early-Stage Breast Cancer

Holowatyj detailed the benefits of a conference like that of the American Association for Cancer Research Annual Meeting 2021, which presents opportunities for thought leaders to come together.

All News